Palifermin vs P-15
Head-to-head comparison of Palifermin (Recombinant Human Keratinocyte Growth Factor (KGF, FGF7)) and P-15 (Synthetic Collagen Type I Cell-Binding Peptide (P-15)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Palifermin | P-15 |
|---|---|---|
| Category | Recovery & Healing | Recovery & Healing |
| Full Name | Recombinant Human Keratinocyte Growth Factor (KGF, FGF7) | Synthetic Collagen Type I Cell-Binding Peptide (P-15) |
| Molecular Weight | 16.3 kDa | 1500 Da |
| Half-Life | 4–6 hours | N/A |
| Amino Acids | 140 | 15 |
| Typical Dose | 60 µg/kg/day | device-dependent local loading |
| Route | Intravenous | Local/Implant |
| Purity | ≥98% | ≥98% |
| Studies Count | 250 | 150 |
| Research Status | Clinical | Clinical |
Palifermin Benefits
- ✓epithelial protection
- ✓mucosal regeneration
- ✓barrier restoration
- ✓reduced inflammatory injury
P-15 Benefits
- ✓improves osteoblast attachment
- ✓supports scaffold osteointegration
- ✓enhances bone fill
- ✓may aid periodontal regeneration
Palifermin Dosing
IV 60 µg/kg/day for 3 days before and 3 days after insult|research protocols vary|short courses only
P-15 Dosing
embedded in scaffold or graft material|local application|single procedural exposure
Palifermin Side Effects
- ⚠rash
- ⚠taste changes
- ⚠edema
- ⚠arthralgia
P-15 Side Effects
- ⚠local irritation
- ⚠inflammation
- ⚠hypersensitivity
Research Overview
Palifermin
Palifermin is clinically established for mucosal protection and has been studied for epithelial repair in other tissues. The strongest evidence is for epithelial resilience and regeneration rather than direct dermal remodeling.
P-15
P-15 is a real literature-backed peptide used to improve biomaterial performance in bone repair settings. Most of the evidence is device- or scaffold-based rather than as a free systemic peptide.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.